Allogene Therapeutics, Inc. announced its financial results for Q4 and the full year 2025, highlighting a cash position of $258.3 million and ongoing clinical trials for its CAR T therapies. The company is focused on advancing its pipeline and maintaining a cash runway into 2028.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.